

P
R
E
S
S

R
E
L
E
A
S
E

Evry, France, 28 May 2004

ObeTherapy Biotechnology filled a patent describing a new high throughput screening assay.

ObeTherapy Biotechnology, a biotechnology company based at the Genopole® Biopark in Evry (France), announced today that it has filled a fourth patent. This patent protects a new technology of cellular high throughput screening using a reporter gene.

“I am sure that this new technology will interest potential partners from the pharmaceutical industry because it combines high specific signal at a very low cost” declares Dr Georges Gaudriault, ObeTherapy’s scientific director.

This new patent will strengthen ObeTherapy patents portfolio which were granted during the years 2000 and 2002: these patents protects the use of our targets for obesity treatment, a rapid and sensitive biochemical assay and several chemical entities as potential lead compounds for obesity treatment

ObeTherapy Biotechnology dedicates its research to new molecules for the treatment of obesity, hypercholesterolaemia and diabetes of type II. Dr Itzik Harosh, PhD, founder and CSO, is a specialist in molecular biology, HTS and drug discovery and has an international experience in the field of obesity. While most of Itzik's colleagues conduct their research on the genetic characterization of obesity, the novel approach of ObeTherapy consists of the analysis of the mechanisms at work in slim phenotype. This approach permitted the identification of many potential therapeutic targets actually being validated.

Contact: Dr. Itzik Harosh, Founder and CSO
Tel. 33-160878904
Fax. 33-160878999
E. mail: iharosh@obetherapy.com
<http://www.obetherapy.com/>